A MULTICENTER, UNCONTROLLED CLINICAL INVESTIGATION OF THE CONTRACEPTIVE EFFICACY, CYCLE CONTROL, AND SAFETY OF A NEW LOW-DOSE ORAL-CONTRACEPTIVE CONTAINING 20 MU-G ETHINYL ESTRADIOL AND 100 MU-G LEVONORGESTRELOVER 6 TREATMENT CYCLES

The aim of the trial was to demonstrate the contraceptive efficacy of a new low dose oral contraceptive containing 20 mu g ethinyl estradiol and 100 mu g levonorgestrel and to observe cycle control and safety. Data from 805 treated women resulted in 4400 treatment cycles. One pre gnancy occurred while on the trial medication as a result of method fa ilure, resulting in a Pearl index of 0.29. Cycle control was good, and cycle length as well as duration and intensity of withdrawal bleeding were not significantly changed during the trial. Intermenstrual bleed ing usually occurred as spotting and decreased considerably during the treatment phase. Spotting alone was reported in 12.4% of cycles, brea kthrough bleeding alone in 4.5% of cycles, and breakthrough bleeding a nd spotting together in 1.4% of treatment cycles. The rate of absence of withdrawal bleeding declined throughout the trial to 2.4% in cycle 6. There were no serious adverse events related to treatment, and most adverse events were those commonly observed in clinical trials with o ral contraceptives. Headache, breast tension, and nausea were reported by 17.3%, 11.0%, and 7.7% of the women, respectively. There were no c linically relevant changes in laboratory parameters, blood pressure, o r weight. in this trial, the new low dose oral contraceptive containin g 20 mu g ethinyl estradiol and 100 mu g levonorgestrel was shown to b e effective, safe, and well tolerated. Cycle control was found to be g ood and there was a low incidence of adverse events. (C) 1997 Elsevier Science Inc. All rights reserved.